CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Medtech firm Baxter Q3 profit beats on Infusion Systems growth; raises 2026 outlook

By Reuters News


Overview

  • Global medtech firm's Q3 revenue grew 5% yr/yr, beating analyst expectations

  • Adjusted EPS for Q3 was down 16% yr/yr but beat analyst expectations

  • Company raised full-year 2026 sales and adjusted EPS outlook


Outlook

  • Baxter raises 2026 reported sales growth outlook to 4%-5% from 3%-4%

  • Company now sees 2026 organic sales growth of 3%-4%, up from 2%-3%

  • Baxter expects 2026 adjusted EPS of $2.05-$2.15, up from $1.95-$2.15


Result Drivers

  • INFUSION SYSTEMS & IV SOLUTIONS - Co said growth in Infusion Systems, Drug Compounding and IV Solutions drove Medical Products & Therapies segment sales

  • CARE & CONNECTIVITY SOLUTIONS - Co attributed Healthcare Systems & Technologies segment growth to demand for Global Surgical Solutions, Patient Support Systems and Front Line Care


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$2.98 bln

$2.91 bln (12 Analysts)

Q3 Adjusted EPS

Beat

$0.58

$0.52 (13 Analysts)

Q3 Net Income

$294 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 13 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

  • Wall Street's median 12-month price target for Baxter International Inc. is $27.00, about 6% above its October 28 closing price of $25.46

  • The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago


Reuters Recommended Reads

  • Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption

  • Oct 28 - Align Technology Q3 revenue slightly beats estimates

  • Oct 28 - Boston Scientific warns of tough 2027 on China pricing, heart-device weakness


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.